Idol star caps Janssen's UGC IBD awareness contest

Share this article:
Idol star caps Janssen's UGC IBD awareness contest
Idol star caps Janssen's UGC IBD awareness contest
Janssen Biotech wrapped up its IBD Icons campaign on Sunday with an American Idol star crowning the winners of the user-generated content contest at a benefit for the Crohn's & Colitis Foundation of America (CCFA).

Season 10 Idol finalist Casey Abrams recognized the two winners—Crohn's sufferer Doug Yakich of Glendale, California and Kansas City, Missouri's Katie Jeter-Boldt, who, like Abrams, has ulcerative colitis—at a concert kicking off the Zappos.com Rock n' Roll Las Vegas Marathon and ½ Marathon, proceeds of which went to benefit IBD Icons partner CCFA. The finalists were selected by Abrams and a panel of CCFA judges, while the winners were chosen by an online poll that drew nearly 150,000 votes.

Janssen markets Remicade, which is indicated to treat a number of autoimmune diseases—including Crohn's and ulcerative colitis, both of which are included in IBD, along with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis—though the campaign was unbranded.

Abrams, who was paid for his participation in the campaign, was diagnosed with ulcerative colitis two years ago and suffered a flare-up while competing on American Idol, managing to finish sixth despite the disease.

“At the time, having a UC flare-up in the middle of the competition seemed like an obstacle, this wall I had to climb over,” said Abrams in a statement, “but with IBD Icons, I feel that we, everyone who entered and the fans who voted, are making a real difference in the way people see this disease.”
Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?